Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have received a consensus recommendation of “Hold” from the ten ratings firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $8.00.

A number of analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lowered shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a research note on Tuesday, September 16th. Needham & Company LLC increased their target price on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Stifel Nicolaus lifted their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a report on Monday, November 17th. Finally, Guggenheim raised Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Monday, October 27th.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $1.77 on Thursday. The company has a market cap of $295.75 million, a P/E ratio of -1.20 and a beta of 3.12. The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. Neumora Therapeutics has a twelve month low of $0.61 and a twelve month high of $11.57. The company’s 50-day moving average price is $2.31 and its 200-day moving average price is $1.75.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). On average, sell-side analysts forecast that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Insider Activity

In other Neumora Therapeutics news, Director Kristina Burow acquired 1,915,700 shares of the stock in a transaction dated Monday, October 27th. The stock was acquired at an average cost of $2.61 per share, with a total value of $4,999,977.00. Following the transaction, the director owned 6,046,907 shares in the company, valued at $15,782,427.27. The trade was a 46.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Daljit Singh Aurora sold 114,703 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total value of $307,404.04. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 26.80% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Legacy Private Trust Co. acquired a new position in Neumora Therapeutics in the third quarter valued at $25,000. Jump Financial LLC acquired a new stake in shares of Neumora Therapeutics in the first quarter valued at approximately $25,000. CWM LLC grew its position in shares of Neumora Therapeutics by 41.8% during the second quarter. CWM LLC now owns 35,750 shares of the company’s stock worth $26,000 after acquiring an additional 10,537 shares during the last quarter. Catalyst Funds Management Pty Ltd purchased a new stake in Neumora Therapeutics in the 2nd quarter valued at $29,000. Finally, Virtu Financial LLC acquired a new stake in Neumora Therapeutics during the 3rd quarter worth $31,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.